News
The US Food and Drug Administration on Wednesday approved Gilead Sciences’ twice-yearly injection to prevent HIV - a move the ...
Gilead Sciences (NASDAQ:GILD) has demonstrated a strong performance this year, with its stock up 18% compared to the S&P ...
Gilead has been a leader in HIV innovation for decades. Now, we're proud to share that one of our researchers, Moupali Das, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results